ESEyk Schellenberger

Eyk Schellenberger

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eyk Schellenberger has a total of 168 co-authors. Here are the top co-authors by number of shared publications:

  • Akvile Haeckel

    Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin Charitéplatz 1

    11 shared publications
  • Bernd Hamm

    Department of Radiology Charité – Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin and Humboldt – Universität zu Berlin Berlin Germany

    6 shared publications
  • Fei Ni

    Department of Radiology, Charité-Universitätsmedizin Berlin, Charitéplatz 1, Berlin, Germany

    4 shared publications
  • Jing Guo

    Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin Charitéplatz 1

    4 shared publications
  • Jörg Schnorr

    Department of Radiology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, D-10117 Berlin, Germany

    4 shared publications
  • Lynn Jeanette Savic

    Department of Radiology Charité – Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin and Humboldt – Universität zu Berlin Berlin Germany

    4 shared publications

Latest Publications

  • Open Access

    Molecular MRI Reveals Macrophage‐Enriched Peritumoral Immune Remodeling After Incomplete Ablation in Liver Cancer

    by Yubei He, Han Xu, Julian M. M. Rogasch, Nikolaus Berndt, Jing Guo, Eyk Schellenberger, Akvile Häckel, Luisa Heidemann, Friederike Hesse, Yu Liu, et al.

    Incomplete image‐guided ablation can promote local tumor progression by reshaping the residual tumor microenvironment toward immunosuppression, yet noninvasive biomarkers of this process remain limited. Here, a translational multiparametric PET/MRI strategy was developed to monitor macrophage‐associated microenvironmental remodeling after incomplete microwave ablation (iMWA) in orthotopic VX2 liver tumors. Twenty‐four tumor‐bearing rabbits were assigned to untreated control, early post‐iMWA (short‐term), or late post‐iMWA (long‐term) groups and underwent clinical 3 T PET/MRI, including diffusion‐weighted imaging, dynamic contrast‐enhanced MRI, [ 1 8 F]FDG PET, and T2‐weighted MRI before and after administration of Eu‐VSOP. Eu‐VSOP‐enhanced MRI revealed a hypointense peritumoral rim after iMWA, with the largest rim‐to‐liver signal decrease and rim thickness observed in the long‐term group. Prussian blue staining and LA‐ICP‐ToF‐MS demonstrated preferential iron and europium enrichment in macrophage‐rich, CD206‐associated peritumoral regions. Histology and proteomics further demonstrated increased CD206 and MMP‐9 expression, extracellular matrix remodeling, immunosuppressive myeloid‐associated changes, and metabolic reprogramming in viable residual tumors, accompanied by altered [ 1 8 F]FDG uptake. Together, these findings indicate that incomplete ablation induces a temporally evolving, macrophage‐rich immunosuppressive peritumoral niche and support the potential of Eu‐VSOP‐enhanced multiparametric PET/MRI for noninvasive monitoring of post‐ablation microenvironmental remodeling.

  • Open Access

    Longitudinal Multifrequency MR Elastography Reveals Biomechanical Signatures of Progression in a Translational Liver Tumor Model

    by Justus Ramtke, Friederike Hesse, Lasse Noack, Justus Klockner, Yubei He, Yu Liu, Yanglei Wu, Robin Schmidt, Selma Saclier, Salma A. S. Abosabie, et al.

    Conventional magnetic resonance imaging (MRI) often detects liver tumors after morphologic and vascular changes become apparent, whereas biomechanical alterations may precede visible tumor formation. Here, we evaluate multifrequency magnetic resonance elastography (mMRE)‐derived shear wave speed (SWS) and phase angle (ϕ) covering stiffness and viscosity as non‐invasive biomechanical imaging markers for liver cancer formation and progression in a translational rabbit model. VX2 liver tumor‐bearing New Zealand White rabbits underwent five longitudinal multiparametric MRI scans over 14 days, including mMRE at clinically relevant frequencies on a 3 Tesla scanner. SWS and ϕ maps were compared with apparent diffusion coefficient (ADC) maps, histopathology, and proteomics. Tumor SWS and ϕ increased 2–3 days after implantation and were significantly higher than liver at two weeks (SWS: p = .002; ϕ: p = .008). Tumor ADC decreased significantly only from days 11–13 onward (day 14: p = .02). Histopathology and proteomics demonstrated tumoral enrichment of collagen, proteoglycan, and glycosaminoglycan pathways compared to liver, suggesting matrix remodeling as a key contributor to increased stiffness and viscosity measured by mMRE. The early elevation of SWS and ϕ preceding ADC changes highlights mMRE as a promising tool for detecting tumor‐associated biomechanical remodeling and enabling earlier liver cancer diagnosis and monitoring beyond conventional MRI.

  • Open Access

    Multiplexed Enzyme Activity Microscopy by Semi-quantitative, Ratiometric Enzyme Activity MALDI Mass Spectrometry Imaging

    by Hamidreza Hojjat, Petra Henklein, Akvile Haeckel, Grit Nebrich, Sylwia Handzik, Pedro Augusto Dantas de Moraes, Jing Guo, Justus Ramtke, Yubei He, Lynn Jeanette Savic, et al.

    Enzymes are often tightly regulated and exist in inactive forms. Therefore, rather than mere presence, it is the enzyme’s activity that catalyzes cellular and tissue functions. However, multiplex activity mapping of enzymes in situ is particularly challenging. To address this, we introduce multiplexed enzyme activity MALDI–MSI (MEA–MSI), a ratiometric, semi-quantitative method that allows multiplex in situ visualization of enzyme activities in zinc-fixed tissue sections. To accomplish this, a library of 31 MEA–MSI substrates targeting proteases, kinases, histone acetyltransferases, and glycosyltransferases was synthesized. Each substrate is designed so that the masses of these substrates and their enzymatic products are distinct, enabling their simultaneous pixel-wise detection within tissue sections. A ratiometric calculation procedure was used to estimate the relative enzyme activity and compensate for tissue-dependent ionization bias, which is a general problem in MALDI–MSI. MEA–MSI was applied to healthy mouse liver, a murine hepatocellular carcinoma (HCC) model, and an incomplete microwave-ablated (iMWA) rabbit VX2 liver tumor model. The resulting activity maps revealed distinct regional enzyme activity patterns across tumor and normal tissues. Correlation and network analyses showed related enzyme activities and related groups, while unsupervised clustering and Uniform Manifold Approximation and Projection (UMAP) analysis reproduced histological patterns. Because MEA–MSI relies on enzymatic amplification, it is not restricted to the detection of highly abundant enzymes and enables multiplexed, spatially resolved readouts of enzyme activity in situ, providing a framework for comparative spatial enzymology.

  • Open Access

    [Fe-EOB-tCDTA] generates strong contrast in the blood but not in the liver, despite inhibiting cellular [Gd-EOB-DTPA]2- uptake and partial liver excretion

    by Fei Ni, Akvile Haeckel, Hamidreza Hojjat, Mathias Schannor, Heike Traub, Eyk Schellenberger

    Objective: Iron-based contrast agents (IBCAs) have potential as alternatives to Gd-based contrast agents (GBCAs), intending to address the long-term safety concerns associated with gadolinium. We investigated [Fe-EOB- t CDTA] as a potential alternative to [Gd-EOB-DTPA] 2 - for liver magnetic resonance imaging (MRI). Materials and methods: [Fe-EOB- t CDTA] was synthesized by reacting the monoanhydride of t CDTA with 4-ethoxybenzylamine followed by iron chelation. Its kinetic stability was spectrophotometrically evaluated using a zinc stress test. The T1 relaxivity was measured in water and serum at 1.41 T, 37 °C and 3 T, 23 °C. Cellular cytotoxicity against liver-derived BRL-3A cells was evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays. The uptake of [Fe-EOB- t CDTA] by liver cells was investigated using LA-ICP-MS, in competition with [Gd-EOB-DTPA] 2 - . T1 contrast effects in BALB/c mice were evaluated by DCE-MRI. Results: [Fe-EOB- t CDTA] exhibited higher kinetic stability than [Fe-( t CDTA)] - and demonstrated a r 1 of 1.94 and 2.45 mM -1 s -1 at 1.4 and 3 T in serum. No significant differences in the short-term cytotoxicity were observed between [Gd-EOB-DTPA] 2 - and [Fe-EOB- t CDTA]. [Fe-EOB- t CDTA] inhibited [Gd-EOB-DTPA] 2 - uptake in BRL-3A liver cells. [Fe-EOB- t CDTA] (0.2 mmol/kg) demonstrated a comparable blood peak RE% compared to [Gd-DO3A-butrol] (0.1 mmol/kg). However, RE of [Gd-EOB-DTPA] 2- in liver at a clinical dose was significantly higher than that of [Fe-EOB- t CDTA] at both injection doses. Conclusion: [Fe-EOB- t CDTA] provides comparable blood enhancement to [Gd-DO3A-butrol] and exhibits hepatobiliary excretion like [Gd-EOB-DTPA] 2 - but without a comparable liver contrast. [Fe-EOB- t CDTA] may serve as an alternative to nonspecific GBCAs, particularly for patients with renal insufficiency and a contraindication to GBCAs. Relevance statement: This study reports on the synthesis and in vitro and in vivo characterization of the iron complex [Fe-EOB- t CDTA]. This complex demonstrates strong blood contrast and liver excretion, though it lacks strong liver contrast. This complex could serve as an extracellular contrast agent, particularly for patients with reduced kidney clearance. Key Points: [Fe-EOB- t CDTA] was synthesized as a novel iron-based MRI T1 contrast agent with liver excretion. [Fe-EOB- t CDTA] generated a strong blood enhancement effect and exhibited hepatobiliary excretion. Negative charge is crucial to the hepatic uptake and long-lasting liver enhancement. Graphical

  • Open Access

    Longitudinal in vivo MR elastography reveals whole-liver viscoelastic involvement in a murine model of hepatocellular carcinoma

    by Pedro Augusto Dantas de Moraes, Yasmine Safraou, Karolina Krehl, Akvile Häckel, Tobias Haase, Susanne Metzkow, Rafaela Vieira da Silva, Yalei Zang, Jonas Röder, Anja A. Kühl, et al.

    Cancer cells actively shape their microenvironment and adapt the physical and biomechanical properties of the host tissue. However, for organs like the liver, especially in vivo, it remains unclear at what rate and spatial extent macroscopic viscoelastic properties change during formation of a cancer-permissive environment. Using clinical multifrequency magnetic resonance elastography (MRE) in a mouse model of hepatocellular carcinoma (HCC), we identified surprisingly early and large-scale viscoelasticity changes leading to whole-liver biomechanical involvement stretching far beyond the local cancer microenvironment. Widespread liver softening began two weeks after HCC inoculation, followed by a decrease in tissue viscosity and fluidity two weeks later, preceding any macroscopic evidence of local tumor growth. In contrast, local lesions with stiff-rigid biomechanical properties were not detectable by standard MRI and MRE until five to six weeks post-injection. Furthermore, tumor viscoelasticity correlated with that of the host liver, also suggesting a possible widespread adaptation of the biomechanical properties beyond the tumor margins and its local niche during early liver colonization. The observed large-scale viscoelastic signature, detectable just two weeks after tumor cells injection, could serve as a non-invasive imaging biomarker to inform physicians about tumor niche formation and liver cancer progression long before any macroscopic manifestation of solid tumors.


  • Open Access

    High-resolution quantitative mapping of extracellular pH by ratiometric MRI with iron chelates in a tumor mouse model

    by Honglan Mi, Philipp Boehm-Sturm, Akvile Haeckel, Ying Li, Susanne Mueller, Fei Ni, Harald Kratz, Marco Foddis, Jing Xie, Eyk Schellenberger

    Purpose: The aim of this study was to generate quantitative extracellular pH maps of tumors using a combination of a pH-sensitive iron chelate-based contrast agent (IBCA) and a pH-insensitive IBCA for concentration measurement, which we termed ratiometric pH magnetic resonance imaging (RpH-MRI). Methods: The pH-sensitive IBCA of ethylenediamine-trans-cyclohexane diamine tetraacetic acid (Fe-en-tCDTA) was synthesized, along with the pH-insensitive IBCAs of trans-cyclohexane diamine tetraacetic acid (Fe-tCDTA) and diethylenetriamine-N,N,N′,N″,N″-pentaacetic acid (Fe-DTPA). The pH-dependent T1 contrast effects of these chelates were compared in water and serum phantoms at 0.94 T, 3 T and 7 T. For in vivo pH mapping of tumors at 7 T, 4T1 breast cancer cells were inoculated subcutaneously into the flanks of the BALB/c mice. RpH-MRI was performed with two sequential intravenous applications: first a pH-insensitive IBCA, followed by the pH-sensitive IBCA at the same dose (0.25 or 0.5 mmol/kg) with an interval of either 30 or 60 min. Quantitative pH maps were generated by calculating T1, S0, and relative maximum enhancement maps of the two injections, together with pH-dependent T1-relaxivity parameters derived from in vitro measurements of the pH-sensitive IBCA and pH-insensitive control IBCA. Results: The T1 relaxivity (r1) of Fe-en-tCDTA was highly pH dependent, being approximately 2.7 times higher at pH 5.5 than at neutral pH, whereas Fe-DTPA and Fe-tCDTA showed stable r1 values between pH 5.5–7.4. In vivo, the time to maximum signal intensity (TMI) of the tumors of Fe-DTPA as control was comparable to that of Fe-en-tCDTA (2.57 ± 1.34 min vs. 2.683 ± 0.89 min, p = 0.7596, paired t test, 4 mice, 7 tumors) as well as for Fe-tCDTA as control versus Fe-en-tCDTA (3.30 ± 1.17 min vs. 3.627 ± 1.12 min, p = 0.2101, paired t test, 7 mice, 13 tumors), suggesting similar pharmacokinetics. The concentration distribution at TMI of the control chelates was assumed to be the same as that of the second injected Fe-en-tCDTA. The dynamic contrast enhanced MRI curve of the first injection of Fe-DTPA returned to baseline after 20–30 min, whereas Fe-tCDTA took 30–60 min to reach baseline. Calculated core and rim pH values were 6.512 ± 0.182 and 6.742 ± 0.121, respectively (p < 0.0001, paired t test, 11 mice, 20 tumors) with core areas showing lower chelate concentrations but higher T1 relaxivity; the mean tumor-wide pH value was 6.632 ± 0.140. Conclusion: Our results demonstrate the potential of high-resolution RpH-MRI based on pH-sensitive and pH-insensitive IBCAs for mapping tumor extracellular pH and concentration distribution.


  • Comparison of Iron(III)-Trans-1,4-Diaminocyclohexane-tCDTA and Iron(III)-Trans-1,4-Diaminocyclohexane-tCDTA-Dimer With Gadobutrol for T1 Contrast Enhancement in DCE-MRI

    by Fei Ni, Akvile Haeckel, Hamidreza Hojjat, Honglan Mi, Harald Kratz, Jing Xie, Eyk Schellenberger

    Purpose: This study evaluated the T1 enhancement of the 2 iron-based contrast agents (IBCAs), [Fe( trans-t CDTA)] + and [Fe( trans-Di-t CDTA)], in blood and other organs compared with a gadolinium-based contrast agent (GBCA) in DCE-MRI, as well as their in vitro toxicity and the stability of the IBCAs compared to [Fe-( t CDTA)] − . Methods: Iron(III) chelates of trans-t CDTA and trans-Di-t CDTA were synthesized and characterized. The T1 relaxivity of IBCAs and gadobutrol was measured at 3T using human whole blood samples. In vitro toxicity was assessed by cytotoxicity of IBCAs and gadobutrol against BRL-3A using MTT viability assays. Kinetic stability was evaluated spectrophotometrically using a zinc stress test (2.5 mM ZnCl 2 ). The T1 contrast in mice was measured using a dynamic T1-weighted gradient-echo sequence. DCE-MRI was performed with 0.17 mmol/kg or 0.35 mmol/kg [Fe( trans-t CDTA)] + , 0.1 mmol/kg [Fe( trans-Di-t CDTA)], and 0.1 mmol/kg gadobutrol. DCE time curves in different organs were evaluated using a 2-phase exponential decay function. Results: [Fe( trans-t CDTA)] + and [Fe( trans-Di-t CDTA)] showed T1 relaxivities in human whole blood at 3T comparable to gadobutrol. No significant differences in short-term cytotoxicity were found between gadobutrol and iron chelates. [Fe( trans-Di-t CDTA)] had a higher kinetic stability than [Fe-( t CDTA)] − , and [Fe( trans-t CDTA)] + had a lower stability in the presence of zinc chloride and phosphate. [Fe( trans-t CDTA)] + showed lower relative blood enhancement at 0.17 mmol/kg ( P = 0.0025) but comparable at 0.35 mmol/kg ( P = 0.4739) versus gadobutrol at 0.1 mmol/kg. [Fe( trans-Di-t CDTA)] showed a similar enhancement to gadobutrol at 0.1 mmol/kg ( P = 0.5238). Max relative enhancement (RE%) were 131.0 ± 18.0, 93.6 ± 9.4, 144.0 ± 15.4, and 143.2 ± 12.3; blood half-lives (rapid phase/slow phase) were 2.3/15.0 minutes, 1.5/59.7 minutes, 1.9/177.1 minutes, and 1.5/27.5 minutes for gadobutrol, [Fe( trans-t CDTA)] + at 0.17 mmol/kg or 0.35 mmol/kg, and [Fe( trans-Di-t CDTA)]. Conclusion: [Fe( trans-Di-t CDTA)] provided comparable contrast enhancement and kinetics to gadobutrol at the same molecular dose (double the metal dose), is very stable, and could serve as an alternative to nonspecific GBCA, thereby avoiding potential long-term gadolinium toxicity and retention concerns as well as environmental gadolinium deposition. [Fe( trans-t CDTA)] + required a higher dose and showed delayed clearance in blood and other organs.


  • Open Access

    Long circulating XTEN864-HGV-Apoptin fusion protein for selective cancer therapy

    by Liu Yang, Akvile Haeckel, Nicola Beindorff, Simon Marc Levin Poetzsch, Honglan Mi, Fei Ni, Hamidreza Hojjat, Winfried Brenner, Pedro Augusto Dantas de Moraes, Jing Guo, et al.


  • Open Access

    The Effects of Hypoxia on the Immune–Metabolic Interplay in Liver Cancer

    by Yubei He, Han Xu, Yu Liu, Stefan Kempa, Carolina Vechiatto, Robin Schmidt, Emine Yaren Yilmaz, Luisa Heidemann, Jörg Schnorr, Susanne Metzkow, et al.

    M2-like macrophages promote tumor growth and cancer immune evasion. This study used an in vitro model to investigate how hypoxia and tumor metabolism affect macrophage polarization. Liver cancer cells (HepG2 and VX2) and macrophages (THP1) were cultured under hypoxic (0.1% O2) and normoxic (21% O2) conditions with varying glucose levels (2 g/L or 4.5 g/L). Viability assays and extracellular pH (pHe) measurements were conducted over 96 hours. Macrophages were exposed to the tumor-conditioned medium (TCM) from the cancer cells, and polarization was assessed using arginase and nitrite assays. GC-MS-based metabolic profiling quantified TCM meta-bolites and correlated them with M2 polarization. The results showed that pHe in TCMs decreased more under hypoxia than normoxia (p < 0.0001), independent of glucose levels. The arginase assay showed hypoxia significantly induced the M2 polarization of macrophages (control group: p = 0.0120,0.1%VX2-TCM group: p = 0.0149, 0.1%HepG2-TCM group: p < 0.0001, 0.1%VX2-TCMHG group: p = 0.0001, and 0.1%HepG2-TCMHG group: p < 0.0001). TCMs also induced M2 polarization under normoxic conditions, but the strongest M2 polarization occurred when both tumor cells and macrophages were incubated under hypoxia with high glucose levels. Metabolomics revealed that several metabolites, particularly lactate, were correlated with hypoxia and M2 polarization. Under normoxia, elevated 2-amino-butanoic acid (2A-BA) strongly correlated with M2 polarization. These findings suggest that targeting tumor hypoxia could mitigate immune evasion in liver tumors. Lactate drives acidity in hypoxic tumors, while 2A-BA could be a therapeutic target for overcoming immunosuppression in normoxic conditions.


  • Open Access

    Long-circulating XTEN864-annexin A5 fusion protein for phosphatidylserine-related therapeutic applications

    by Akvile Haeckel, Lena Ascher, Nicola Beindorff, Sonal Prasad, Karolina Garczyńska, Jing Guo, Eyk Schellenberger

    Annexin A5 (anxA5) is a marker for apoptosis, but has also therapeutic potential in cardiovascular diseases, cancer, and, due to apoptotic mimicry, against dangerous viruses, which is limited by the short blood circulation. An 864-amino-acid XTEN polypeptide was fused to anxA5. XTEN864-anxA5 was expressed in Escherichia coli and purified using XTEN as tag. XTEN864-anxA5 was coupled with DTPA and indium-111. After intravenous or subcutaneous injection of 111In-XTEN864-anxA5, mouse blood samples were collected for blood half-life determination and organ samples for biodistribution using a gamma counter. XTEN864-anxA5 was labeled with 6S-IDCC to confirm binding to apoptotic cells using flow cytometry. To demonstrate targeting of atherosclerotic plaques, XTEN864-anxA5 was labeled with MeCAT(Ho) and administered intravenously to atherosclerotic ApoE−/− mice. MeCAT(Ho)-XTEN864-anxA5 was detected together with MeCAT(Tm)-MAC-2 macrophage antibodies by imaging mass cytometry (CyTOF) of aortic root sections. The ability of anxA5 to bind apoptotic cells was not affected by XTEN864. The blood half-life of XTEN864-anxA5 was 13 h in mice after IV injection, markedly longer than the 7-min half-life of anxA5. 96 h after injection, highest amounts of XTEN864-anxA5 were found in liver, spleen, and kidney. XTEN864-anxA5 was found to target the adventitia adjacent to atherosclerotic plaques. XTEN864-anxA5 is a long-circulating fusion protein that can be efficiently produced in E. coli and potentially circulates in humans for several days, making it a promising therapeutic drug.